InternationalUSRemember you can easily switch between MIP US and MIP International at any time

European Commission claims pharma competition success

Legal Media Group


The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission

In a statement published on January 31, the Commission said that its third annual survey had found that 11% of antitrust settlements were potentially problematic from an antitrust point of view, compared to 21% when the pharmaceutical sector enquiry was...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

ICYMI: Our report on this week's #SCOTUS ruling in Star Athletica v Varsity Brands https://t.co/Rf3TWplNUrhttps://t.co/TrZ5YcvKQr

Mar 24 2017 01:35 ·  reply ·  retweet ·  favourite
ManagingIP profile

@Oblon_IP @PatentPostGrant Congratulations Scott! #mipawards

Mar 24 2017 01:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

@KellyIPllp Well done to all at the firm!

Mar 24 2017 02:16 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements